


Ninth AACR-Japanese Cancer Association Joint Conference:

# BREAKTHROUGHS IN BASIC AND TRANSLATIONAL CANCER RESEARCH



 *American Association  
for Cancer Research*  
[www.aacr.org/conferences](http://www.aacr.org/conferences)



February 21-25, 2013

Hyatt Regency Maui  
Maui, HI

## Conference Co-Chairpersons:

### **Tyler Jacks**

David H. Koch Institute for  
Integrative Cancer Research at MIT  
Cambridge, MA, USA

### **Kohei Miyazono**

University of Tokyo  
Tokyo, Japan

Abstract Submission and Award  
Application Deadline Extended:  
**Friday, November 2**

Advance Registration Deadline:  
**Monday, December 17**

# BREAKTHROUGHS IN BASIC AND TRANSLATIONAL CANCER RESEARCH

February 21-25, 2013 • Hyatt Regency Maui • Maui, HI

More than 20 years ago, the American Association for Cancer Research and the Japanese Cancer Association held their first of eight joint conferences. These meetings have been aimed at bringing outstanding American and Japanese researchers together with two goals. The first is to provide a forum for discussion of the latest advances in the broad field of cancer research, both translational/clinical and basic. The second and equally important goal is to provide a mechanism for the interpersonal interactions which foster international collaborations. These conferences have been extremely successful in both areas and are tangible examples of the close relationship between the AACR and the JCA.

The Ninth Joint Conference continues to extend this tradition. The 12 conference sessions will feature outstanding speakers covering topics ranging from basic science to therapeutics, including prevention, epigenetics, and other important areas. Thus, the conference will take a broad view of contemporary cancer research that is intended to be of interest to basic and clinical investigators. The organization and timing of the platform and poster sessions have been designed to maximize interactions. The conference organizers believe that this meeting will catalyze many new collaborations, just as its predecessors have done.

## Conference Co-Chairpersons:

**Tyler Jacks**, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA

**Kohei Miyazono**, University of Tokyo, Tokyo, Japan

## Organizing Committee:

**Lynda Chin**, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**Lisa M. Coussens**, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA

**Mari Kannagi**, Tokyo Medical & Dental University, Tokyo, Japan

**Gou Young Koh**, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea

**Sean J. Morrison**, UT Southwestern Medical Center, Dallas, TX, USA

**Hitoshi Nakagama**, National Cancer Center Research Institute, Tokyo, Japan

**Tomoki Naoe**, Nagoya University Hospital, Nagoya, Japan

**Motoharu Seiki**, University of Tokyo, Institute of Medical Science, Tokyo, Japan

**Jeffrey E. Settleman**, Genentech Inc., South San Francisco, CA, USA

**Phillip A. Sharp**, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA

# SCIENTIFIC PROGRAM AND CONFERENCE SCHEDULE

## Thursday, February 21

### 5:00 p.m.-6:30 p.m. Keynote Session

RNA biology and basic and translational cancer research  
**Phillip A. Sharp**, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA

Targeting essential growth drivers in human cancers  
**Hiroyuki Mano**, Jichi Medical School, Tochigi, Japan

### 6:30 p.m.-8:00 p.m. Opening Reception

## Friday, February 22

### 7:00 a.m.-8:00 a.m. Breakfast/Mentoring Roundtables

### 8:00 a.m.-9:30 a.m. Session 1: Cancer Genomes and Tumor Evolution

Survival of the fittest: Cancer genome evolution towards adaptation  
**Tatsuhiko Shibata**, National Cancer Center Research Institute, Tokyo, Japan

Interrogating the architecture of cancer genomes  
**Peter J. Campbell**, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Genome-wide analyses of pediatric solid tumors  
**Junko Takita**, University of Tokyo, Tokyo, Japan

### 9:30 a.m.-10:00 a.m. Break

### 10:00 a.m.-11:30 a.m. Session 2: Circulating Tumor Cells and Other New Diagnostic Technologies

Bioengineering and clinical applications of circulating tumor cell chips  
**Shyamala Maheswaran**, Massachusetts General Hospital, Charlestown, MA, USA

PLS3 expression in circulating blood is a good marker for colon cancer recurrence  
**Masaki Mori**, Osaka University, Osaka, Japan

The clinical application of circulating tumor DNA  
**Luis A. Diaz**, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

### 11:30 a.m.-3:30 p.m. Free Time

### 3:30 p.m.-5:00 p.m. Session 3: Noncoding RNAs

Senescence-associated microRNAs, a novel approach to tumor suppression

**Hidetoshi Tahara**, Hiroshima University, Hiroshima, Japan

microRNA reprogramming in cancer: Mechanisms and consequences  
**Joshua Mendell**, UT Southwestern Medical Center, Dallas, TX, USA

Linking RNA to human health and disease  
**John L. Rinn**, Harvard University, Cambridge, MA, USA

### 5:00 p.m.-7:00 p.m. Poster Session A

# SCIENTIFIC PROGRAM AND CONFERENCE SCHEDULE

## Saturday, February 23

**7:00 a.m.-8:00 a.m. Breakfast/Mentoring Roundtables**

**8:00 a.m.-9:30 a.m. Session 4: DNA Damage Response**

DNA damage response and cellular senescence in cancer

**Eiji Hara**, Japanese Foundation for Cancer Research, Tokyo, Japan

Harnessing genetic dependencies in cancer therapy

**Alan Ashworth**, Institute of Cancer Research, London, United Kingdom

Complex regulation of homologous recombination by E3 ligases

**Shinichiro Nakada**, Osaka University, Osaka, Japan

**9:30 a.m.-10:00 a.m. Break**

**10:00 a.m.-11:30 a.m. Session 5: Epigenetics and Cancer Cell States**

Epigenetic plasticity and its clinical implications in human neoplasia

**Yutaka Kondo**, Aichi Cancer Center, Nagoya, Japan

The regulation of melanoma metastasis

**Sean J. Morrison**, UT Southwestern Medical Center, Dallas, TX, USA

Dysregulation of noncoding RNA genes and its clinical application

**Hiromu Suzuki**, Sapporo Medical University, Sapporo, Japan

**11:30 a.m.-3:30 p.m. Free Time**

**3:30 p.m.-5:00 p.m. Session 6: Cancer Progression and Metastasis**

Molecular characterization of lung cancer progression

**Tyler Jacks**, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA

Significance of hypoxia-inducible factor in cancer progression and metastasis

**Shinae Kondoh**, Tokyo Institute of Technology, Tokyo, Japan

The systemic environment as an important determinant of malignancy

**Sandra S. McAllister**, Brigham and Women's Hospital, Boston, MA, USA

**5:00 p.m.-7:00 p.m. Poster Session B**

## Sunday, February 24

**7:00 a.m.-8:00 a.m. Breakfast/Mentoring Roundtables**

**8:00 a.m.-9:30 a.m. Session 7: Tumor Microenvironment**

Molecular control of tumor vessel destabilization

**Gou Young Koh**, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea

Chronic inflammation and cancer: Translating basic science to the clinic

**Lisa M. Coussens**, Oregon Health & Science University's Knight Cancer Institute, Portland, OR, USA

Mint3 promotes tumor malignancy in cancer and stromal cells

**Takeharu Sakamoto**, University of Tokyo, Institute of Medical Science, Tokyo, Japan

**9:30 a.m.-10:00 a.m. Break**

# SCIENTIFIC PROGRAM AND CONFERENCE SCHEDULE

## 10:00 a.m.-11:30 a.m. **Session 8: Cancer Immunology and Immunotherapy**

Immune checkpoint blockade in cancer therapy: New insights and opportunities

**James P. Allison**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Impact of innate and acquired immune responses in adult T-cell leukemia

**Mari Kannagi**, Tokyo Medical and Dental University, Tokyo, Japan

microRNAs and myeloid-derived suppressor cells in tumor immune escape

**Qingqing Wang**, Zhejiang University School of Medicine, Hangzhou, China

## 11:30 a.m.-3:30 p.m. **Free Time**

## 3:30 p.m.-5:00 p.m. **Session 9: Preclinical Models**

GEM models in translational research

**Lynda Chin**, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Novel strategies for targeting cancer stem cells

**Hideyuki Saya**, Keio University, Tokyo, Japan

Contributions of the tumor microenvironment to chemoresistance

**Mikala Egeblad**, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

## 5:00 p.m.-7:00 p.m. **Poster Session C**

## Monday, February 25

## 7:00 a.m.-8:00 a.m. **Breakfast/Mentoring Roundtables**

## 8:00 a.m.-9:30 a.m. **Session 10: Signaling and Systems Biology**

Targeted sequencing of Asian cancer phenotypes

**Patrick Tan**, Duke-NUS Graduate Medical School Singapore, Singapore

A systems approach to understanding and predicting therapeutic response

**Joe W. Gray**, Oregon Health & Science University's Knight Cancer Institute, Portland, OR, USA

Statistical gene network analysis for understanding cancer heterogeneity

**Seiya Imoto**, University of Tokyo, Institute of Medical Science, Tokyo, Japan

## 9:30 a.m.-10:00 a.m. **Break**

## 10:00 a.m.-11:30 a.m. **Session 11: Cancer Prevention**

Energy balance and inflammation in cancer prevention and prognosis

**Cornelia M. Ulrich**, German Cancer Research Center, Heidelberg, Germany

GWAS revealed the roles of gene-environmental interaction in carcinogenesis

**Koichi Matsuda**, University of Tokyo, Institute of Medical Science, Tokyo, Japan

Targeting the DNA repair network as a novel approach for cancer prevention

**Guang Peng**, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

## 11:30 a.m.-3:00 p.m. **Free Time**

## 3:00 p.m.-4:30 p.m. **Session 12: Targeted Therapies and Resistance**

Title to be announced

**Jeffrey E. Settleman**, Genentech, Inc., South San Francisco, CA, USA

TTF-1: A double-edged sword in lung adenocarcinoma

**Takashi Takahashi**, Nagoya University, Nagoya, Japan

Biological mechanisms of resistance to targeted therapies

**Katerina A. Politi**, Yale Cancer Center, New Haven, CT, USA

## 4:30 p.m.-6:30 p.m. **Poster Session D**

## 7:00 p.m.-10:00 p.m. **Closing Reception and Banquet**

# GENERAL INFORMATION

## Registration

Attendee registration includes admission to all lecture sessions, poster sessions, the opening reception on February 21, the closing reception and banquet on February 25, conference continental breakfasts on February 22, 23, 24, and 25, refreshment breaks, and refreshments during the poster sessions on February 22, 23, 24, and 25. To register for the conference please visit [www.aacr.org/aacr-jca](http://www.aacr.org/aacr-jca).

	<b>ADVANCE Until December 17</b>	<b>REGULAR After December 17</b>
<b>AACR Members</b>		
Active and Affiliate	\$635	\$795
Associate and Emeritus	\$415	\$545
Student (Undergraduate and High School)	\$50	\$50
<b>JCA Members</b>	\$635	\$795
<b>Nonmembers</b>	\$635	\$795
Academic, Government and Not-for-Profit Institutions	\$805	\$945
Industry	\$985	\$1,085
Pre-/Postdoctoral Student <sup>1</sup>	\$475	\$615
<b>Spouse/Guest</b>	\$150	\$150

<sup>1</sup>Nonmember pre-/postdoctoral students must have their registrar, dean or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

The spouse/guest fee is only for meals and social activities listed above. It does NOT admit individuals to lecture sessions.

## AACR Membership

AACR membership is available to individuals who are interested in joining the AACR and registering for this conference at the discounted member rates. AACR membership offers an array of benefits, including reduced subscription rates to the AACR's seven scientific journals; abstract sponsorship privileges for AACR Annual Meetings; networking and scientific exchange with leading researchers; and more. The AACR is also eager to support the exchange of knowledge and research with investigators who are located in countries with emerging economies. Significantly reduced membership dues are available for these investigators.

Individuals interested in joining the AACR and registering at the advance registration rate must submit an application no later than December 10, 2012. Only individuals who are listed on the membership rolls as members in good standing as of February 15, 2013, will be accorded the privilege of registering for the conference at the member rates noted above. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she applied, then the candidate will need to register at the nonmember rate. Additional information on AACR membership categories, as well as application forms and submission instructions, is available at [www.aacr.org](http://www.aacr.org). Contact the AACR Membership Department at (215) 440-9300 with any questions.

## Refund Policy

Requests for refunds must be made in writing and received by the AACR Meetings Department before January 25, 2013. Refund requests may be sent by fax to (215) 351-9165 or by e-mail to [meetings@aacr.org](mailto:meetings@aacr.org). There will be a \$75 administrative fee for processing cancellations received before January 25, 2013. After January 25, no refunds can be made.

# GENERAL INFORMATION

## Accommodations and Travel to Maui, HI

For more information about the hotel, how to book your room online, and travel to the conference, please visit [www.aacr.org/aacr-jca](http://www.aacr.org/aacr-jca).

## Abstract Submission

Each participant will be given the opportunity to present one poster of his or her work. It is expected that the abstract will include original data not previously published in a peer-reviewed journal or the proceedings of a national meeting. Only those abstracts that have been reviewed by the Program Committee may be presented. Abstracts must be submitted online; paper abstracts will not be accepted. Complete abstract submission details, including the abstract categories, may be found on the conference website at [www.aacr.org/aacr-jca](http://www.aacr.org/aacr-jca). The abstract submission deadline is **Friday, November 2, 11:59 p.m. U.S. EDT**.

## Oral Presentations From Highly Rated Abstracts

Oral presentations of highly rated abstracts will be integrated within selected sessions. All abstracts submitted by the October 22 deadline will be considered. Anyone selected to present an oral presentation will be notified approximately three weeks after the abstract submission deadline.

## Financial Support for Attendance

A variety of award programs are available to offset a portion of the registration, travel, and subsistence expenses incurred in attending this conference. For more information on financial support, please visit the conference website at [www.aacr.org/aacr-jca](http://www.aacr.org/aacr-jca). The deadline to apply for an award is **Friday, November 2**.

## Assistance for Registrants with Disabilities

The AACR's conferences are accessible to all investigators. Registrants with special requirements for transportation, hotel accommodations, or other facilities connected with the conference should inform the AACR by checking the appropriate box when registering or by contacting the AACR Meetings Department at (215) 440-9300 or [meetings@aacr.org](mailto:meetings@aacr.org).

Ninth AACR-Japanese Cancer Association Joint Conference:

# BREAKTHROUGHS IN BASIC AND TRANSLATIONAL CANCER RESEARCH

February 21-25, 2013

Hyatt Regency Maui  
Maui, HI

**Conference Co-Chairpersons:**

**Tyler Jacks**

David H. Koch Institute for  
Integrative Cancer Research at MIT  
Cambridge, MA, USA

**Kohei Miyazono**

University of Tokyo  
Tokyo, Japan

Abstract Submission and Award  
Application Deadline Extended:  
**Friday, November 2**

Advance Registration Deadline:  
**Monday, December 17**